Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Saccharo
AddedFeb 15, 2024
UpdatedJun 18, 2026
Saccharo

Saccharo

Series A

Saccharo, a therapeutic biotech start-up, pioneers in immuno-oncology, developing treatments for cancer and novel diseases.

HQ
Oakland, CA, US
Founded
2017
Overview
Compare
Fundraising
Employees
Website

Saccharo, founded in 2017 by Sherry Martin-Moe and Gregory Moe in Oakland, California, is a therapeutic biotech start-up focused on immuno-oncology. The company develops innovative treatments for cancer and other novel diseases, leveraging a unique polysaccharide-based immune shielding pathway discovered by its co-founder. Saccharo’s approach allows for multiple killing effects, a broad therapeutic window, and applications across various cancers, aiming to revolutionize cancer therapy with a predicted safety profile.

Notable figures affiliated with Saccharo include its founders, Sherry Martin-Moe and Gregory Moe, who bring significant expertise to the company. Saccharo has made key strides in the preclinical stage, developing a promising pipeline of cancer therapies. The discovery of the polysaccharide mechanism has positioned Saccharo as a pioneer in the field, potentially transforming cancer treatment and offering new hope for patients worldwide.

Saccharo - Similar Companies

Glycyx logo

Glycyx

glycyx.com

Shasqi logo

Shasqi

shasqi.com

Glycologix logo

Glycologix

glycologix.com

Cancervax logo

Cancervax

cancervax.com

Guardian Bio logo

Guardian Bio

guardian-bio.com

Gliknik logo

Gliknik

gliknik.com

Saros Therapeutics logo

Saros Therapeutics

sarostx.com

Seneca Therapeutics logo

Seneca Therapeutics

Sutro Biopharma logo

Sutro Biopharma

sutrobio.com

Onchilles Pharma logo

Onchilles Pharma

Immune-Onc Therapeutics logo

Immune-Onc Therapeutics

immuneonc.com

Concarlo Holdings logo

Concarlo Holdings

concarlo.com

Arrogene logo

Arrogene

Oncofactor logo

Oncofactor

oncofactor.com

Sarcio logo

Sarcio

sarcioinc.com

Saccharo - Quick Facts

Who are Saccharo's competitors?

Companies similar to Saccharo include Glycyx, Shasqi, Glycologix and Cancervax.

When was Saccharo founded?

Saccharo was founded in 2017.

Where is Saccharo's headquarters located?

Saccharo's headquarters is located in Oakland, CA, US.

When was Saccharo's last funding round?

Saccharo's most recent funding round was for $7.4M (USD) in August 2022.

How much has Saccharo raised to-date?

As of Aug 22, 2022, Saccharo has raised a total of $7.4M (USD).

How many employees does Saccharo have?

Saccharo has 4 employees as of Feb 5, 2024.

Saccharo - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Main Product
  • Cancer Therapies
Tags
  • Biotech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified